Zhibin Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Zhibin Chen has a total of 79 co-authors. Here are the top co-authors by number of shared publications:
- Priyadharshini Devarajan
Department of Pathology, University of Massachusetts Medical School, Worcester, MA 01605
6 shared publications Jen Bon Lui
Department of Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, FL
5 shared publicationsJason Miska
Department of Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, FL 33136; and
4 shared publications- Kevin H. Toomer
Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD
4 shared publications Xiaodong Cai
Department of Electrical and Computer Engineering, University of Miami, Miami, FL, USA
4 shared publicationsAmanda M. Honan
Department of Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, FL, USA
3 shared publications
Latest Publications
- Open Access
Single-Cell Transcriptomics Reveals Tumorigenic Lineages and Interactions Persisting and Evolving From Premalignancy to Cancer in the Stomach
Background & Aims: Gastric cancer is often diagnosed at advanced stages, making the premalignant window critical for early detection. However, the epithelial changes that characterize this stage remain poorly defined. We used CTLA4-knockdown (CTLA4KD) mice, which model human CTLA4 insufficiency-associated gastric cancer, that develops autoimmune gastritis, metaplasia, and adenocarcinoma, to define molecular changes across disease progression. Methods: Single-cell RNA sequencing and 40-color spectral flow cytometry were performed on gastric tissue across premalignant and cancer stages. We evaluated epithelial lineage relationships, cell-cell communication pathways, and candidate markers at the transcript and protein levels in murine and human gastric adenocarcinoma. Results: We identified a metaplastic/tumorigenic population in CTLA4KD mice that emerged in premalignancy with a chief cell transcriptomic origin. Cell-cell communication analysis revealed a progressive increase in fibronectin (FN1) signaling from premalignancy through cancer, transitioning from stromal to autocrine signaling in the metaplastic/tumorigenic population. Expression of Embigin (EMB), a fibronectin receptor, increased at both transcript and protein levels in premalignancy and remained elevated in cancer. EMB⁺ epithelial cells co-expressed CD133, a cancer stem cell marker, consistent with a stem-like phenotype. EMB expression was also higher in human gastric adenocarcinoma than in matched normal tissue. Conclusions: Using a model that captures the full histopathological cascade of gastric tumorigenesis, we delineate single-cell transcriptional programs that persist and evolve from premalignancy to adenocarcinoma. In-depth computational analyses identified novel markers involved in cell-cell communication during tumorigenesis, including EMB, an epithelial marker that persists from premalignancy through cancer in the murine model and validated in human gastric adenocarcinoma, suggesting EMB as a marker of premalignant progression. Graphic What You Need to Know: Background and Context: The cellular and molecular changes that drive gastric premalignancy toward invasive cancer remain poorly defined, leaving no reliable way to identify which premalignant lesions will progress. New Findings: We identified a tumorigenic epithelial population present in premalignancy and persisting into cancer, accompanied by increased fibronectin signaling and sustained Embigin expression across disease progression. Limitations: We defined the premalignant-to-cancer transition in a mouse model and validated a marker in human gastric adenocarcinoma. Single-cell studies of human gastric premalignancy to cancer progression are needed to confirm these findings. Clinical Research Relevance: Defining epithelial changes that persist from premalignancy through cancer may help distinguish lesions progressing toward malignancy from those remaining stable. Embigin may represent a candidate marker of this transition, supporting future studies aimed at improving risk stratification and earlier identification of patients most likely to develop gastric cancer. Basic Research Relevance: This study defines cellular and molecular changes during the transition from gastric premalignancy to cancer. It identifies a tumorigenic population arising from chief cells that persists across disease stages, as well as changes in fibronectin signaling and Embigin expression associated with progression of premalignancy toward invasive cancer. Lay Summary: We identified markers of stomach cells on the pathway to becoming cancer cells in animal models, and these markers may provide a tool for early detection before invasive cancer develops.
Open AccessSingle-Cell Transcriptomics Reveals Tumorigenic Lineages and Interactions Persisting and Evolving From Premalignancy to Cancer in the Stomach
Background & Aims: Gastric cancer is often diagnosed at advanced stages, making the premalignant window critical for early detection. However, the epithelial changes that characterize this stage remain poorly defined. We used CTLA4-knockdown (CTLA4KD) mice, which model human CTLA4 insufficiency-associated gastric cancer, that develops autoimmune gastritis, metaplasia, and adenocarcinoma, to define molecular changes across disease progression. Methods: Single-cell RNA sequencing and 40-color spectral flow cytometry were performed on gastric tissue across premalignant and cancer stages. We evaluated epithelial lineage relationships, cell-cell communication pathways, and candidate markers at the transcript and protein levels in murine and human gastric adenocarcinoma. Results: We identified a metaplastic/tumorigenic population in CTLA4KD mice that emerged in premalignancy with a chief cell transcriptomic origin. Cell-cell communication analysis revealed a progressive increase in fibronectin (FN1) signaling from premalignancy through cancer, transitioning from stromal to autocrine signaling in the metaplastic/tumorigenic population. Expression of Embigin (EMB), a fibronectin receptor, increased at both transcript and protein levels in premalignancy and remained elevated in cancer. EMB⁺ epithelial cells co-expressed CD133, a cancer stem cell marker, consistent with a stem-like phenotype. EMB expression was also higher in human gastric adenocarcinoma than in matched normal tissue. Conclusions: Using a model that captures the full histopathological cascade of gastric tumorigenesis, we delineate single-cell transcriptional programs that persist and evolve from premalignancy to adenocarcinoma. In-depth computational analyses identified novel markers involved in cell-cell communication during tumorigenesis, including EMB, an epithelial marker that persists from premalignancy through cancer in the murine model and validated in human gastric adenocarcinoma, suggesting EMB as a marker of premalignant progression. Graphic What You Need to Know: Background and Context: The cellular and molecular changes that drive gastric premalignancy toward invasive cancer remain poorly defined, leaving no reliable way to identify which premalignant lesions will progress. New Findings: We identified a tumorigenic epithelial population present in premalignancy and persisting into cancer, accompanied by increased fibronectin signaling and sustained Embigin expression across disease progression. Limitations: We defined the premalignant-to-cancer transition in a mouse model and validated a marker in human gastric adenocarcinoma. Single-cell studies of human gastric premalignancy to cancer progression are needed to confirm these findings. Clinical Research Relevance: Defining epithelial changes that persist from premalignancy through cancer may help distinguish lesions progressing toward malignancy from those remaining stable. Embigin may represent a candidate marker of this transition, supporting future studies aimed at improving risk stratification and earlier identification of patients most likely to develop gastric cancer. Basic Research Relevance: This study defines cellular and molecular changes during the transition from gastric premalignancy to cancer. It identifies a tumorigenic population arising from chief cells that persists across disease stages, as well as changes in fibronectin signaling and Embigin expression associated with progression of premalignancy toward invasive cancer. Lay Summary: We identified markers of stomach cells on the pathway to becoming cancer cells in animal models, and these markers may provide a tool for early detection before invasive cancer develops.
- Open Access
A critical role of epithelial MHCII in initiation of autoimmune tumorigenesis and sustaining premalignancy growth in the stomach
Autoimmunity is emerging as a new etiology for early-onset gastric cancer (GC). However, it remains unclear what molecular pathways drive the initiation and progression of autoimmune tumorigenesis. Given that Major Histocompatibility Complex Class II (MHCII) is the strongest genetic risk factor for many autoimmune diseases, we hypothesized that MHCII-mediated autoantigen presentation drives tumorigenic differentiation of epithelial cells. Here we show that epithelial MHCII, rather than MHCII from immune cells, plays an essential role in the initiation of autoimmunity-driven tumorigenic differentiation of gastric epithelial cells, which was characterized by increased expression of cancer-associated markers with immune-evasive and stem-like features that potentiate premalignant progression. In addition, we show that early gastric premalignancy is reversible upon the removal of epithelial MHCII. This study reveals that epithelial MHCII antigen presentation is essential in the early stages of autoimmune-driven gastric tumorigenesis and highlight epithelial MHCII as a potential biomarker or therapeutic target in early interventions of autoimmunity-driven cancer development.
Open AccessA critical role of epithelial MHCII in initiation of autoimmune tumorigenesis and sustaining premalignancy growth in the stomach
Autoimmunity is emerging as a new etiology for early-onset gastric cancer (GC). However, it remains unclear what molecular pathways drive the initiation and progression of autoimmune tumorigenesis. Given that Major Histocompatibility Complex Class II (MHCII) is the strongest genetic risk factor for many autoimmune diseases, we hypothesized that MHCII-mediated autoantigen presentation drives tumorigenic differentiation of epithelial cells. Here we show that epithelial MHCII, rather than MHCII from immune cells, plays an essential role in the initiation of autoimmunity-driven tumorigenic differentiation of gastric epithelial cells, which was characterized by increased expression of cancer-associated markers with immune-evasive and stem-like features that potentiate premalignant progression. In addition, we show that early gastric premalignancy is reversible upon the removal of epithelial MHCII. This study reveals that epithelial MHCII antigen presentation is essential in the early stages of autoimmune-driven gastric tumorigenesis and highlight epithelial MHCII as a potential biomarker or therapeutic target in early interventions of autoimmunity-driven cancer development.
- Open Access
Deep Semi-Supervised Survival Analysis for Predicting Cancer Prognosis
The Cox Proportional Hazards (PH) model is widely used in survival analysis. Recently, artificial neural network (ANN)-based Cox-PH models have been developed. However, training these Cox models with high-dimensional features typically requires a substantial number of labeled samples containing information about time-to-event. The limited availability of labeled data for training often constrains the performance of ANN-based Cox models. To address this issue, we employed a deep semi-supervised learning (DSSL) approach to develop single- and multi-modal ANN-based Cox models based on the Mean Teacher (MT) framework, which utilizes both labeled and unlabeled data for training. We applied our model, named Cox-MT, to predict the prognosis of several types of cancer using data from The Cancer Genome Atlas (TCGA). Our single-modal Cox-MT models, utilizing TCGA RNA-seq data or whole slide images, significantly outperformed the existing ANN-based Cox model, Cox-nnet, using the same data set across four types of cancer considered. As the number of unlabeled samples increased, the performance of Cox-MT significantly improved with a given set of labeled data. Furthermore, our multi-modal Cox-MT model demonstrated considerably better performance than the single-modal model. In summary, the Cox-MT model effectively leverages both labeled and unlabeled data to significantly enhance prediction accuracy compared to existing ANN-based Cox models trained solely on labeled data.
Open AccessDeep Semi-Supervised Survival Analysis for Predicting Cancer Prognosis
The Cox Proportional Hazards (PH) model is widely used in survival analysis. Recently, artificial neural network (ANN)-based Cox-PH models have been developed. However, training these Cox models with high-dimensional features typically requires a substantial number of labeled samples containing information about time-to-event. The limited availability of labeled data for training often constrains the performance of ANN-based Cox models. To address this issue, we employed a deep semi-supervised learning (DSSL) approach to develop single- and multi-modal ANN-based Cox models based on the Mean Teacher (MT) framework, which utilizes both labeled and unlabeled data for training. We applied our model, named Cox-MT, to predict the prognosis of several types of cancer using data from The Cancer Genome Atlas (TCGA). Our single-modal Cox-MT models, utilizing TCGA RNA-seq data or whole slide images, significantly outperformed the existing ANN-based Cox model, Cox-nnet, using the same data set across four types of cancer considered. As the number of unlabeled samples increased, the performance of Cox-MT significantly improved with a given set of labeled data. Furthermore, our multi-modal Cox-MT model demonstrated considerably better performance than the single-modal model. In summary, the Cox-MT model effectively leverages both labeled and unlabeled data to significantly enhance prediction accuracy compared to existing ANN-based Cox models trained solely on labeled data.
- Open Access
Machine Learning for Predicting and Maximizing the Response of Breast Cancer Patients to Neoadjuvant Therapy
Purpose: Neoadjuvant therapy (NAT) is an established treatment for certain high-risk, locally advanced, or unresectable breast cancers, often facilitating breast-conserving surgery. Recent studies show that achieving pathologic complete response (pCR) after NAT correlates with higher event-free survival rates. Thus, accurate prediction of pCR is essential for personalizing breast cancer (BC) treatment to minimize side effects and improve effectiveness. Methods: We used a machine learning model named XGBoost to predict pCR in BC patients. The classifier was trained on the expression values of 4,000 genes to predict pCR in ten arms of the I-SPY2 clinical trial. Based on these predictions, we developed a strategy to maximize pCR likelihood and identified influential genes using the importance scores from the model. Results: XGBoost models for three arms, Pembrolizumab, ABT 888 plus carboplatin, and T-DM1 plus pertuzumab, achieved the highest prediction accuracies with areas under the receiver operation characteristic curve (AUCs) of 0.814, 0.792, and 0.788, respectively. If treatment assignments followed the XGBoost predictions, pCR rates for nine out of ten I-SPY2 arms could increase significantly, by 9.9% to 29.1% compared to trial results. Key genes associated with pCR were identified for each arm. The expression levels of some genes, including lower expression of ABDH1, AMZ1, BAIAP3 and SYTL4 and higher expression of DENND1C, HMGB3, HMMR, PLEKHF1 and RASEF, were associated with pCR in multiple arms. Conclusion: The machine learning models developed in this study provide accurate pCR predictions, improve pCR rates, and may find clinical applications to enhance the treatment for BC patients.
Open AccessMachine Learning for Predicting and Maximizing the Response of Breast Cancer Patients to Neoadjuvant Therapy
Purpose: Neoadjuvant therapy (NAT) is an established treatment for certain high-risk, locally advanced, or unresectable breast cancers, often facilitating breast-conserving surgery. Recent studies show that achieving pathologic complete response (pCR) after NAT correlates with higher event-free survival rates. Thus, accurate prediction of pCR is essential for personalizing breast cancer (BC) treatment to minimize side effects and improve effectiveness. Methods: We used a machine learning model named XGBoost to predict pCR in BC patients. The classifier was trained on the expression values of 4,000 genes to predict pCR in ten arms of the I-SPY2 clinical trial. Based on these predictions, we developed a strategy to maximize pCR likelihood and identified influential genes using the importance scores from the model. Results: XGBoost models for three arms, Pembrolizumab, ABT 888 plus carboplatin, and T-DM1 plus pertuzumab, achieved the highest prediction accuracies with areas under the receiver operation characteristic curve (AUCs) of 0.814, 0.792, and 0.788, respectively. If treatment assignments followed the XGBoost predictions, pCR rates for nine out of ten I-SPY2 arms could increase significantly, by 9.9% to 29.1% compared to trial results. Key genes associated with pCR were identified for each arm. The expression levels of some genes, including lower expression of ABDH1, AMZ1, BAIAP3 and SYTL4 and higher expression of DENND1C, HMGB3, HMMR, PLEKHF1 and RASEF, were associated with pCR in multiple arms. Conclusion: The machine learning models developed in this study provide accurate pCR predictions, improve pCR rates, and may find clinical applications to enhance the treatment for BC patients.
- Open Access
- 1 June 2024
- Published by Wolters Kluwer Health in Clinical and Translational Gastroenterology
- Vol. 15 (9) , e1
Stromal-Like Cells Are Found in Peripheral Blood of Patients With Inflammatory Bowel Disease and Correlate With Immune Activation State
INTRODUCTION: Recent studies have identified a critical role of stromal-immune cell interactions in immunity and immune tolerance. Transcriptomic profiling has implicated stromal cells in immune-mediated disorders including the 2 common forms of inflammatory bowel disease (IBD), Crohn's disease (CD), and ulcerative colitis (UC). Stromal-immune interactions may edify inflammatory state and the development of IBD-related complications such as fibrosis, yet the lack of protein markers has hampered studying stromal-immune perturbation. METHODS: In this study, we designed a 40-color spectral flow cytometry assay to characterize hematopoietic and nonhematopoietic cells in intestinal biopsies and matched blood samples from patients with CD or UC. RESULTS: We identified circulating stromal-like cells that are significantly more abundant in IBD blood samples than in healthy controls. Those cells expressed podoplanin (PDPN), a commonly used marker for fibroblasts, and they were associated with activated and memory T and B cells and altered natural killer cell, monocyte, and macrophage populations. PDPN+ cells in the blood correlated with PDPN+ cells in the colon. Principal component analysis distinctly separated healthy blood samples from IBD blood samples, with stromal-like cells and B-cell subtypes dominating the IBD signature; Pearson correlation detected an association between PDPN+ stromal-like cells and B-cell populations in IBD blood and gut biopsies. DISCUSSION: These observations suggest that PDPN+ cells in the blood may serve as a biomarker of IBD. Understanding the relationship between stromal cells and immune cells in the intestine and the blood may provide a window into disease pathogenesis and insight into therapeutic targets for IBD.
- 1 June 2024
- Published by Wolters Kluwer Health in Clinical and Translational Gastroenterology
- Vol. 15 (9) , e1
Open AccessStromal-Like Cells Are Found in Peripheral Blood of Patients With Inflammatory Bowel Disease and Correlate With Immune Activation State
INTRODUCTION: Recent studies have identified a critical role of stromal-immune cell interactions in immunity and immune tolerance. Transcriptomic profiling has implicated stromal cells in immune-mediated disorders including the 2 common forms of inflammatory bowel disease (IBD), Crohn's disease (CD), and ulcerative colitis (UC). Stromal-immune interactions may edify inflammatory state and the development of IBD-related complications such as fibrosis, yet the lack of protein markers has hampered studying stromal-immune perturbation. METHODS: In this study, we designed a 40-color spectral flow cytometry assay to characterize hematopoietic and nonhematopoietic cells in intestinal biopsies and matched blood samples from patients with CD or UC. RESULTS: We identified circulating stromal-like cells that are significantly more abundant in IBD blood samples than in healthy controls. Those cells expressed podoplanin (PDPN), a commonly used marker for fibroblasts, and they were associated with activated and memory T and B cells and altered natural killer cell, monocyte, and macrophage populations. PDPN+ cells in the blood correlated with PDPN+ cells in the colon. Principal component analysis distinctly separated healthy blood samples from IBD blood samples, with stromal-like cells and B-cell subtypes dominating the IBD signature; Pearson correlation detected an association between PDPN+ stromal-like cells and B-cell populations in IBD blood and gut biopsies. DISCUSSION: These observations suggest that PDPN+ cells in the blood may serve as a biomarker of IBD. Understanding the relationship between stromal cells and immune cells in the intestine and the blood may provide a window into disease pathogenesis and insight into therapeutic targets for IBD.
- 1 October 2023
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 94 (2S) , S93-S98
An Overview of Miami CDEIPI and a Showcase of Team Science and Cutting-Edge Research Driven by Students
Background: The Miami-CFAR Diversity, Equity & Inclusion Pathway Initiative (Miami CDEIPI) is designed to promote a diverse scientific workforce that reflects the communities at the highest risk of HIV in South Florida. Setting and Methods: The focus of the Miami CDEIPI is to help train the next generation of Underrepresented Minorities (URM) and Black, Indigenous, People of Color (BIPOC) in HIV/AIDS-related research through a team science experience. The Miami CDEIPI objectives are to facilitate the interaction of URM/BIPOC students with the network of CFAR-affiliated investigators and to enable these students to access the cutting-edge technologies at the Miami-CFAR and the Sylvester Comprehensive Cancer Center and other resources at the University of Miami. Results: Five URM/BIPOC students supported by the program in year 1 have been carrying out projects in collaboration with mentors at their parent institution and Miami-CFAR investigators. The students used the state-of-the-art laboratories and core facilities. They began their research with a proposal designed to integrate the cutting-edge technologies now available to them. Their training included participation in Miami-CFAR–sponsored activities such as seminars, an annual conference, and a national HIV workshop. Candidates in the Miami CDEIPI are in the process of developing their research proposals, integrating cutting-edge technologies into their doctoral dissertation research. Their projects are now in the completion phase. Conclusions: The Miami CDEIPI focuses its resources on one of the conspicuous gaps in the career paths of URM/BIPOC researchers—the dearth of leading URM/BIPOC scientists in the field. The Miami CDEIPI provides a professional network that supports the participation of URM/BIPOC trainees in innovative research and career skill training.
- 1 October 2023
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 94 (2S) , S93-S98
An Overview of Miami CDEIPI and a Showcase of Team Science and Cutting-Edge Research Driven by Students
Background: The Miami-CFAR Diversity, Equity & Inclusion Pathway Initiative (Miami CDEIPI) is designed to promote a diverse scientific workforce that reflects the communities at the highest risk of HIV in South Florida. Setting and Methods: The focus of the Miami CDEIPI is to help train the next generation of Underrepresented Minorities (URM) and Black, Indigenous, People of Color (BIPOC) in HIV/AIDS-related research through a team science experience. The Miami CDEIPI objectives are to facilitate the interaction of URM/BIPOC students with the network of CFAR-affiliated investigators and to enable these students to access the cutting-edge technologies at the Miami-CFAR and the Sylvester Comprehensive Cancer Center and other resources at the University of Miami. Results: Five URM/BIPOC students supported by the program in year 1 have been carrying out projects in collaboration with mentors at their parent institution and Miami-CFAR investigators. The students used the state-of-the-art laboratories and core facilities. They began their research with a proposal designed to integrate the cutting-edge technologies now available to them. Their training included participation in Miami-CFAR–sponsored activities such as seminars, an annual conference, and a national HIV workshop. Candidates in the Miami CDEIPI are in the process of developing their research proposals, integrating cutting-edge technologies into their doctoral dissertation research. Their projects are now in the completion phase. Conclusions: The Miami CDEIPI focuses its resources on one of the conspicuous gaps in the career paths of URM/BIPOC researchers—the dearth of leading URM/BIPOC scientists in the field. The Miami CDEIPI provides a professional network that supports the participation of URM/BIPOC trainees in innovative research and career skill training.
- Open Access
- 11 February 2022
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 10, 855191
Editorial: Autoimmunity, Infection and Cancer, an Inflammatory Relationship With Intimate Implication to Cancer Prevention and Immunotherapy
Editorial: Autoimmunity, Infection and Cancer, an Inflammatory Relationship With Intimate Implication to Cancer Prevention and Immunotherapy
- 11 February 2022
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 10, 855191
Open AccessEditorial: Autoimmunity, Infection and Cancer, an Inflammatory Relationship With Intimate Implication to Cancer Prevention and Immunotherapy
Editorial: Autoimmunity, Infection and Cancer, an Inflammatory Relationship With Intimate Implication to Cancer Prevention and Immunotherapy
- 15 September 2021
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 207 (6) , 1530-1544
Lymph Node Stromal Cell–Intrinsic MHC Class II Expression Promotes MHC Class I–Restricted CD8 T Cell Lineage Conversion to Regulatory CD4 T Cells
MHC class I (MHC-I)–restricted CD4+ T cells have long been discovered in the natural repertoire of healthy humans as well as patients with autoimmune diseases or cancer, but the exact origin of these cells remains to be fully characterized. In mouse models, mature peripheral CD8+ T cells have the potential to convert to CD4+ T cells in the mesenteric lymph nodes. This conversion can produce a unique population of MHC-I–restricted CD4+ T cells including Foxp3+ regulatory T cells termed MHC-I–restricted CD4+Foxp3+ T (CI-Treg) cells. In this study we examined the cellular and molecular elements that promote CD8-to-CD4 lineage conversion and the development of CI-Treg cells in mice. Using adoptive transfer and bone marrow chimera experiments, we found that the differentiation of CI-Treg cells was driven by lymph node stromal cell (LNSC)-intrinsic MHC-II expression as opposed to transcytosis of MHC-II from bone marrow–derived APCs. The lineage conversion was accompanied by Runx3 versus ThPOK transcriptional switch. This finding of a new role for LNSCs in vivo led us to develop an efficient tissue culture method using LNSCs to generate and expand CI-Treg cells in vitro. CI-Treg cells expanded in vitro with LNSCs effectively suppressed inflammatory tissue damage caused by pathogenic CD4+ T cells in mouse models of colitis. This study identified a novel role of MHC-II expressed by LNSCs in immune regulation and the potential utilization of LNSCs to generate novel subsets of immune regulatory cells for therapeutic applications. Key Points LNSC MHC-II drives conversion of CD8 T cells to CD4 CI-Treg cells. LNSC coculture helps generate and expand CI-Treg cells in vitro. CI-Treg cells expanded in stromal cell coculture suppress colitis in mice.
- 15 September 2021
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 207 (6) , 1530-1544
Lymph Node Stromal Cell–Intrinsic MHC Class II Expression Promotes MHC Class I–Restricted CD8 T Cell Lineage Conversion to Regulatory CD4 T Cells
MHC class I (MHC-I)–restricted CD4+ T cells have long been discovered in the natural repertoire of healthy humans as well as patients with autoimmune diseases or cancer, but the exact origin of these cells remains to be fully characterized. In mouse models, mature peripheral CD8+ T cells have the potential to convert to CD4+ T cells in the mesenteric lymph nodes. This conversion can produce a unique population of MHC-I–restricted CD4+ T cells including Foxp3+ regulatory T cells termed MHC-I–restricted CD4+Foxp3+ T (CI-Treg) cells. In this study we examined the cellular and molecular elements that promote CD8-to-CD4 lineage conversion and the development of CI-Treg cells in mice. Using adoptive transfer and bone marrow chimera experiments, we found that the differentiation of CI-Treg cells was driven by lymph node stromal cell (LNSC)-intrinsic MHC-II expression as opposed to transcytosis of MHC-II from bone marrow–derived APCs. The lineage conversion was accompanied by Runx3 versus ThPOK transcriptional switch. This finding of a new role for LNSCs in vivo led us to develop an efficient tissue culture method using LNSCs to generate and expand CI-Treg cells in vitro. CI-Treg cells expanded in vitro with LNSCs effectively suppressed inflammatory tissue damage caused by pathogenic CD4+ T cells in mouse models of colitis. This study identified a novel role of MHC-II expressed by LNSCs in immune regulation and the potential utilization of LNSCs to generate novel subsets of immune regulatory cells for therapeutic applications. Key Points LNSC MHC-II drives conversion of CD8 T cells to CD4 CI-Treg cells. LNSC coculture helps generate and expand CI-Treg cells in vitro. CI-Treg cells expanded in stromal cell coculture suppress colitis in mice.
- Open Access
- 21 June 2021
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 9
Autoimmunity as an Etiological Factor of Cancer: The Transformative Potential of Chronic Type 2 Inflammation
Recent epidemiological studies have found an alarming trend of increased cancer incidence in adults younger than 50 years of age and projected a substantial rise in cancer incidence over the next 10 years in this age group. This trend was exemplified in the incidence of non-cardia gastric cancer and its disproportionate impact on non-Hispanic white females under the age of 50. The trend is concurrent with the increasing incidence of autoimmune diseases in industrialized countries, suggesting a causal link between the two. While autoimmunity has been suspected to be a risk factor for some cancers, the exact mechanisms underlying the connection between autoimmunity and cancer remain unclear and are often controversial. The link has been attributed to several mediators such as immune suppression, infection, diet, environment, or, perhaps most plausibly, chronic inflammation because of its well-recognized role in tumorigenesis. In that regard, autoimmune conditions are common causes of chronic inflammation and may trigger repetitive cycles of antigen-specific cell damage, tissue regeneration, and wound healing. Illustrating the connection between autoimmune diseases and cancer are patients who have an increased risk of cancer development associated with genetically predisposed insufficiency of cytotoxic T lymphocyte-associated protein 4 (CTLA4), a prototypical immune checkpoint against autoimmunity and one of the main targets of cancer immune therapy. The tumorigenic process triggered by CTLA4 insufficiency has been shown in a mouse model to be dependent on the type 2 cytokines interleukin-4 (IL4) and interleukin-13 (IL13). In this type 2 inflammatory milieu, crosstalk with type 2 immune cells may initiate epigenetic reprogramming of epithelial cells, leading to a metaplastic differentiation and eventually malignant transformation even in the absence of classical oncogenic mutations. Those findings complement a large body of evidence for type 1, type 3, or other inflammatory mediators in inflammatory tumorigenesis. This review addresses the potential of autoimmunity as a causal factor for tumorigenesis, the underlying inflammatory mechanisms that may vary depending on host-environment variations, and implications to cancer prevention and immunotherapy.
- 21 June 2021
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 9
Open AccessAutoimmunity as an Etiological Factor of Cancer: The Transformative Potential of Chronic Type 2 Inflammation
Recent epidemiological studies have found an alarming trend of increased cancer incidence in adults younger than 50 years of age and projected a substantial rise in cancer incidence over the next 10 years in this age group. This trend was exemplified in the incidence of non-cardia gastric cancer and its disproportionate impact on non-Hispanic white females under the age of 50. The trend is concurrent with the increasing incidence of autoimmune diseases in industrialized countries, suggesting a causal link between the two. While autoimmunity has been suspected to be a risk factor for some cancers, the exact mechanisms underlying the connection between autoimmunity and cancer remain unclear and are often controversial. The link has been attributed to several mediators such as immune suppression, infection, diet, environment, or, perhaps most plausibly, chronic inflammation because of its well-recognized role in tumorigenesis. In that regard, autoimmune conditions are common causes of chronic inflammation and may trigger repetitive cycles of antigen-specific cell damage, tissue regeneration, and wound healing. Illustrating the connection between autoimmune diseases and cancer are patients who have an increased risk of cancer development associated with genetically predisposed insufficiency of cytotoxic T lymphocyte-associated protein 4 (CTLA4), a prototypical immune checkpoint against autoimmunity and one of the main targets of cancer immune therapy. The tumorigenic process triggered by CTLA4 insufficiency has been shown in a mouse model to be dependent on the type 2 cytokines interleukin-4 (IL4) and interleukin-13 (IL13). In this type 2 inflammatory milieu, crosstalk with type 2 immune cells may initiate epigenetic reprogramming of epithelial cells, leading to a metaplastic differentiation and eventually malignant transformation even in the absence of classical oncogenic mutations. Those findings complement a large body of evidence for type 1, type 3, or other inflammatory mediators in inflammatory tumorigenesis. This review addresses the potential of autoimmunity as a causal factor for tumorigenesis, the underlying inflammatory mechanisms that may vary depending on host-environment variations, and implications to cancer prevention and immunotherapy.
- Open Access
- 25 May 2021
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 9
Stromal Cells Underlining the Paths From Autoimmunity, Inflammation to Cancer With Roles Beyond Structural and Nutritional Support
Stromal cells provide structural support and nutrients in secondary lymphoid organs and non-lymphoid tissues. However, accumulating evidence suggests that a complex relationship exists between stromal cells and immune cells. Interactions between immune cells and stromal cells have been shown to influence the pathology of both autoimmunity and cancer. This review examines the heterogeneity of stromal cells within the lymph node and non-lymphoid tissues during both homeostatic and inflammatory conditions, in particular autoimmunity and cancer, with the goal of better understanding the complex and apparently paradoxical relationship between these two classes of diseases. The review surveys potential novel mechanisms involving the interactions between stromal cells and immune cells which may contribute to the development, pathology and underlying connection between autoimmunity and cancer, including potential pathways from autoimmune inflammation to either “hot” or “cold” tumors. These interactions may provide some insights to explain the rising incidence of both autoimmunity and cancer in young women in industrialized countries and have the potential to be exploited in the development of new interventions for preventions and treatments of both autoimmune diseases and cancer.
- 25 May 2021
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 9
Open AccessStromal Cells Underlining the Paths From Autoimmunity, Inflammation to Cancer With Roles Beyond Structural and Nutritional Support
Stromal cells provide structural support and nutrients in secondary lymphoid organs and non-lymphoid tissues. However, accumulating evidence suggests that a complex relationship exists between stromal cells and immune cells. Interactions between immune cells and stromal cells have been shown to influence the pathology of both autoimmunity and cancer. This review examines the heterogeneity of stromal cells within the lymph node and non-lymphoid tissues during both homeostatic and inflammatory conditions, in particular autoimmunity and cancer, with the goal of better understanding the complex and apparently paradoxical relationship between these two classes of diseases. The review surveys potential novel mechanisms involving the interactions between stromal cells and immune cells which may contribute to the development, pathology and underlying connection between autoimmunity and cancer, including potential pathways from autoimmune inflammation to either “hot” or “cold” tumors. These interactions may provide some insights to explain the rising incidence of both autoimmunity and cancer in young women in industrialized countries and have the potential to be exploited in the development of new interventions for preventions and treatments of both autoimmune diseases and cancer.